Imbalance in glycemic control between the treatment and placebo groups in cardiovascular outcome trials in type 2 diabetes

Background Glycated hemoglobin (HbA1c) is accepted as the most reliable marker for assessing chronic glycemia. The present study aimed to investigate glycemic control in cardiovascular outcome trials (CVOTs) performed by pharmaceutical sponsors, at the request of the United States Food and Drug Admi...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Rumiko Shimazawa, Masayuki Ikeda
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Taylor & Francis Group 2019-12-01
Цуврал:	Journal of Pharmaceutical Policy and Practice
Нөхцлүүд:	bias cardiovascular diseases clinical trials drug approval glycated hemoglobin hypoglycemic agents type 2 diabetes mellitus
Онлайн хандалт:	http://dx.doi.org/10.1186/s40545-019-0193-y
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!